Present state of immunosuppressive therapy in liver transplant recipients

Liver Transplantation

Volumn 17, Issue SUPPL. 3, 2011, Pages

  Wiesner, Russell H ^a   Fung, John J ^b  

^a Mayo Clinic   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; BELATACEPT; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; ARTICLE; CELL INTERACTION; CLINICAL PRACTICE; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LIVER TRANSPLANTATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; METABOLIC DISORDER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UNITED STATES; IMMUNOLOGY; METHODOLOGY; REVIEW;

GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION;

EID: 84857180370     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22410     Document Type: Article

References (41)

1. von Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. N Engl J Med 2000; 343: 1020-1034.
2. Choudhuri K, Wiseman D, Brown MH, Gould K, van der Merwe PA. T-cell receptor triggering is critically dependent on the dimensions of its peptide-MHC ligand. Nature 2005;436: 578-582.
3. Zheng H, Jin B, Henrickson SE, Perelson AS, von Andrian UH, Chakraborty AK. How antigen quantity and quality determine T-cell decisions in lymphoid tissue. Mol Cell Biol 2008;28: 4040-4051.
4. Wang D, Matsumoto R, You Y, Che T, Lin XY, Gaffen SL, Lin X. CD3/CD28 costimulation-induced NF-jB activation is mediated by recruitment of protein kinase C-y, Bcl10, and IjB kinase b to the immunological synapse through CARMA1. Mol Cell Biol 2004;24: 164-171.
5. Martinez OM, Rosen HR. Basic concepts in transplant immunology. Liver Transpl 2005;11: 370-381.
6. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351: 2715-2729.
7. Wiesner RH, Ludwig J, van Hoek B, Krom RA. Current concepts in cell-mediated hepatic allograft rejection leading to ductopenia and liver failure. Hepatology 1991; 14(pt 1): 721-729.
8. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997;25: 658-663.
9. US Department of Health and Human Services. 2009 OPTN/SRTR annual report. Liver: recipients: immunosuppression use. Table 9.6. http: //optn.transplant. hrsa.gov/ar2009/iLI-Recipients-immuno.htm?o1/49&g1/42&c1/418.Accessed August 2011.
10. Kowalski RJ, Post DR, Mannon RB, Sebastian A, Wright HI, Sigle G, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006;82: 663-668.
11. Berglund D, Bengtsson M, Biglarnia A, Berglund E, Yamamoto S, von Zur-Mühlen B, et al. Screening of mortality in transplant patients using an assay for immune function. Transpl Immunol 2011;24: 246-250.
12. Sawitzki B, Reinke P, Pascher A, Volk HD. State of the art on the research for biomarkers allowing individual, tailor-made minimization of immunosuppression. Curr Opin Organ Transplant 2010;15: 691-696.
13. Massoud O, Heimbach J, Viker K, Krishnan A, Poterucha J, Sanchez W, et al. Noninvasive diagnosis of acute cellular rejection in liver transplant recipients: a proteomic signature validated by enzyme-linked immunosorbent assay. Liver Transpl 2011;17: 723-732.
14. Pons JA, Ramírez P, Revilla-Nuin B, Pascual D, Baroja- Mazo A, Robles R, et al. Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients. Clin Transplant 2009;23: 329-336.
15. Boudjema K, Camus C, Saliba F, Calmus Y, Salamé E, Pageaux G, et al. Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. Am J Transplant 2011;11: 965-976.
16. Mazariegos GV, Reyes J, Marino IR, Demetris AJ, Flynn B, Irish W, et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 1997;63: 243-249.
17. Neuberger JM, Mamelok RD, Neuhaus P, Pirenne J, Samuel D, Isoniemi H, et al.; for ReSpECT Study Group. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant 2009;9: 327-336.
18. Goralczyk AD, Hauke N, Bari N, Tsui TY, Lorf T, Obed A. Interleukin 2 receptor antagonists for liver transplant recipients: a systematic review and meta-analysis of controlled studies. Hepatology 2011;54: 541-554.
19. Asrani SK, Kim WR, Pedersen RA, Charlton MR, Kremers WK, Therneau TM, et al. Daclizumab induction therapy in liver transplant recipients with renal insufficiency. Aliment Pharmacol Ther 2010;32: 776-786.
20. Eason JD, Loss GE, Blazek J, Nair S, Mason AL. Steroidfree liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial. Liver Transpl 2001;7: 693-697.
21. Eghtesad B, Forrest T, Fijiki M, Diago T, Hodgkinson P, Hashimoto K, et al. A pilot randomized controlled clinical trial of Thymoglobulin (r-ATG) induction with extended delay of calcineurin inhibitor therapy in liver transplantation- interim analysis [abstract]. Liver Transpl 2011; 17(suppl 1): S85.
22. Marcos A, Eghtesad B, Fung JJ, Fontes P, Patel K, Devera M, et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation 2004;78: 966-971.
23. Levitsky J, Thudi K, Ison MG, Wang E, Abecassis M. Alemtuzumab induction in non-hepatitis C positive liver transplant recipients. Liver Transpl 2011;17: 32-37.
24. Firpi RJ, Zhu H, Morelli G, Abdelmalek MF, Soldevila- Pico C, Machicao VI, et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 2006;12: 51-57.
25. Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of ameta-analysis. Liver Transpl 2007;13: 21-29.
26. Irish WD, Arcona S, Bowers D, Trotter JF. Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/ OPTN database. Am J Transplant 2011;11: 1676-1685.
27. ClinicalTrials.gov. Liver fibrosis in patients transplanted for hepatitis C receiving either cyclosporine microemulsion or tacrolimus. http: //clinicaltrials.gov/ct2/show/record/NCT00260208. Accessed August 2011.
28. Jain AB, Hamad I, Rakela J, Dodson F, Kramer D, Demetris J, et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. Transplantation 1998;66: 1395-1398.
29. Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010;51: 1237-1243.
30. Wiesner, R.; for Rapamune Liver Transplant Study Group. The safety and efficacy of sirolimus and low dose tacrolimus versus tacrolimus in de novo orthotopic liver transplant recipients: results from a pilot study [abstract]. Hepatology 2002;36: 208A.
31. Schnitzbauer AA, Zuelke C, Graeb C, Rochon J, Bilbao I, Burra P, et al. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor- free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer 2010;10: 190.
32. Campsen J, Zimmerman MA, Mandell S, Kaplan M, Kam I. A decade of experience using mTOR inhibitors in liver transplantation. J Transplant 2011;2011: 913094.
33. Asrani SK, Leise MD, West CP, Murad MH, Pedersen RA, Erwin PJ, et al. Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis. Hepatology 2010;52: 1360-1370.
34. Schnitzbauer AA, Scherer MN, Rochon J, Sothmann J, Farkas SA, Loss M, et al. Study protocol: a pilot study to determine the safety and efficacy of induction-therapy, de novo MPA and delayed mTOR-inhibition in liver transplant recipients with impaired renal function. PATRONstudy. BMC Nephrol 2010;11: 24.
35. Goralczyk AD, Schnitzbauer A, Tsui TY, Ramadori G, Lorf T, Obed A. A therapeutic exploratory study to determine the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation: CILT. BMC Surg 2010;10: 15.
36. Klintmalm GB, Washburn WK, Rudich SM, Heffron TG, Teperman LW, Fasola C, et al. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007;13: 1521-1531.
37. Lladó L, Fabregat J, Castellote J, Ramos E, Xiol X, Torras J, et al.; for THOSIN Study Group. Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study. Liver Transpl 2008;14: 1752-1760.
38. Vivarelli M, Burra P, La Barba G, Canova D, Senzolo M, Cucchetti A, et al. Influence of steroids on HCV recurrence after liver transplantation: a prospective study. J Hepatol 2007;47: 793-798.
39. Shaked A, Ghobrial RM, Merion RM, Shearon TH, Emond JC, Fair JH, et al.; for A2ALL Study Group. Incidence and severity of acute cellular rejection in recipients undergoing adult living donor or deceased donor liver transplantation. Am J Transplant 2009;9: 301-308.
40. Wiesner RH, Ludwig J, Krom RA, Steers JL, Porayko MK, Gores GJ, Hay JE. Treatment of early cellular rejection following liver transplantation with intravenous methylprednisolone. The effect of dose on response. Transplantation 1994;58: 1053-1056.
41. Wiesner RH, Demetris AJ, Belle SH, Seaberg EC, Lake JR, Zetterman RK, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998;28: 638-645.